Financial Performance - Q2 2025 - Adjusted revenue reached $474 million, a 11.6% year-over-year increase, or 10.4% on a constant currency basis[47] - Gross margin was 47.2%, a 410 basis points increase year-over-year[47] - Adjusted operating margin was 9.2%, a 290 basis points increase year-over-year[47] - Adjusted EPS was $0.35, a 133.3% increase year-over-year, or 126.7% on a constant currency basis[47] Revenue Breakdown by Group - Q2 2025 - Active Group revenue was $356 million, a 16.2% year-over-year increase[49] - Work Group revenue was $108 million, a 2.4% year-over-year increase[51] Financial Outlook - Q3 2025 - Revenue is projected to be between $450 million and $460 million, representing a 3.3% increase at the midpoint, or 2.6% on a constant currency basis[58] - Gross margin is expected to be approximately 47.0%, a 170 basis points increase compared to the previous year[58] - Adjusted operating margin is expected to be approximately 8.3%, a 60 basis points increase compared to the previous year[58] - Adjusted EPS is projected to be between $0.28 and $0.32, representing a 3.4% increase year-over-year at the midpoint[58] FY24 Performance - Adjusted Revenue was $1.75 billion, a 507% increase compared to FY23[7,8] - Adjusted EPS increased 154%[9]

Financial Performance - Capri Holdings' revenue decreased by 60% (-77% Constant Currency) in 1Q Fiscal Year 2026 [11] - Michael Kors' revenue decreased by 59% (-73% Constant Currency) in 1Q26 [18] - Jimmy Choo's revenue decreased by 64% (-92% Constant Currency) in 1Q26 [25] - The adjusted EPS was $050, driven by better than anticipated results at Michael Kors and Jimmy Choo as well as a discrete tax benefit [11] Strategic Initiatives & Outlook - Capri Holdings expects revenue of approximately $815 - $835 million for 2Q26 and approximately $3375 - $345 billion for Fiscal Year 2026 [27] - The company anticipates net interest income of approximately $15 million for 2Q26 and approximately $85 - $95 million for Fiscal Year 2026 [27] - The company expects a diluted earnings per share (Continuing Operations) of approximately $010 - $015 for 2Q26 and approximately $120 - $140 for Fiscal Year 2026 [27] Versace Sale - Capri Holdings entered into an agreement to sell Versace to Prada for $1375 billion in cash [6] - The transaction is expected to close in the second half of calendar 2025 [6] - Capri plans to use the proceeds to substantially reduce debt levels, invest in future growth, and reinstate a share repurchase program in the future [8] Customer Database - The customer database increased by 9% versus prior year [11] - Global database increased 9% year-over-year for Michael Kors [18] - Global database increased 9% year-over-year for Jimmy Choo [25]

Financial Performance - OPENLANE achieved consolidated revenue growth of 9% reaching $481.7 million in Q2 2025[10, 40] - Adjusted EBITDA increased by 21% to $86.7 million[10, 40] - Adjusted EBITDA margin improved by 190 basis points to 18%[40] - Income from continuing operations saw a significant increase of 212% reaching $33.4 million[40] - Adjusted Free Cash Flow increased by 34% to $86.5 million[40] - Operating Adjusted EPS increased by 74% to $0.33[40] Segment Performance - The marketplace segment experienced substantial growth, with dealer vehicles sold increasing by 21%[11] - The finance segment demonstrated strong performance, growing average managed receivables and increasing adjusted EBITDA[11] Guidance - OPENLANE raised its 2025 guidance, with revised expectations for Income from Continuing Operations between $132 million and $140 million[12, 52] - Adjusted EBITDA guidance was revised upward to a range of $310 million to $320 million[12, 53] - Operating Adjusted EPS guidance was also increased to a range of $1.12 to $1.17[53]

Financial Performance - Carlyle reported income before provision for income taxes of $441 million, with a margin of 280% for Q2 2025[3] - Net income attributable to The Carlyle Group Inc common stockholders was $320 million, or $087 per share on a diluted basis for Q2 2025[13] - Distributable Earnings (DE) were $431 million for Q2 2025, or $091 per common share on a post-tax basis[18] - Fee Related Earnings (FRE) were $323 million for Q2 2025[18] - Realized Net Performance Revenues were $88 million for Q2 2025[18] Assets Under Management (AUM) - Total Assets Under Management reached $465 billion as of June 30, 2025, a 7% increase year-over-year[6, 18] - Fee-earning Assets Under Management totaled $325 billion, up 6% year-over-year[18] - Perpetual Capital Fee-earning AUM was $101 billion, representing 31% of total Fee-earning AUM[18] Capital Management - A quarterly dividend of $035 per common share was declared, payable on August 28, 2025[4, 18] - The company repurchased or withheld 23 million shares of common stock in Q2 2025, totaling $104 million[18] - As of June 30, 2025, $06 billion of repurchase capacity remained under the $14 billion repurchase authorization[18]

Financial Performance - Q3 Fiscal 2025 - Revenue increased by 8.7% year-over-year to $80.7 billion[13] - Adjusted diluted EPS increased 19.8% year-over-year to $4.00[10, 12] - Consolidated adjusted operating income grew by 20.6% year-over-year[12] Segment Performance - Q3 Fiscal 2025 - U S Healthcare Solutions segment revenue increased by 8.5% to $72.9 billion, with operating income up 29.1% to $0.9 billion[15, 16] - International Healthcare Solutions segment revenue increased by 10.5% to $7.8 billion, but operating income decreased by 12.9% to $156.2 million[17, 18] - On a constant currency basis, International Healthcare Solutions revenue increased by 8.8% and operating income decreased by 16.2%[17, 18] Fiscal Year 2025 Guidance - Cencora updated its fiscal year 2025 adjusted diluted EPS guidance to a range of $15.85 to $16.00[10] - The company anticipates consolidated revenue growth of approximately 9%[20] - Adjusted operating income is projected to increase by 15% to 16%[20]

Second Quarter 2025 Performance - Second quarter revenue reached $148 million, with organic revenue growth of 6%[13] - Adjusted Earnings Per Share (EPS) increased 31% to $0.21, and Adjusted EBITDA margin increased 23%[13] - Surgical Solutions revenue increased 11% compared to the prior year quarter, driven by double-digit growth in Ultrasonics[39] - Restorative Therapies revenue declined 32% compared to the prior year quarter due to the divestiture of the Advanced Rehabilitation Business, while EXOGEN grew 11%[39] - Pain Treatments revenue increased 1% compared to the prior year quarter[39] Financial Metrics and Guidance - Adjusted Gross Margin increased 50 basis points due to improved product mix[40] - The company ended the second quarter with $33 million in cash and $341 million in debt outstanding[48] - Cash from operations was an inflow of $26 million in the second quarter[48] - The company reaffirms its 2025 financial guidance, projecting net sales in the range of $560 million to $570 million, representing organic growth of 6% to 8%[52] - Adjusted EBITDA is expected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share is projected to be in the range of $0.64 to $0.68[52] Strategic Initiatives and Future Outlook - The company received FDA 510(k) clearance for StimTrial and TalisMann, Peripheral Nerve Stimulation (PNS) products, targeting the chronic peripheral pain market[18, 20] - The PNS market is estimated to be growing above 20% annually in the U S and is expected to exceed $500 million by 2029, with an expected total addressable market of approximately $2 billion[20] - The company plans to invest in a direct sales force in the second half of 2025 and expects TalisMann and StimTrial to potentially generate $100 million or more of revenue[27] - The company forecasts at least 100 basis points of Adjusted EBITDA margin expansion in 2025[30] - The company expects cash from operations in 2025 to nearly double compared to 2024 and expects to reduce net leverage to below 2 5 times by the end of 2025[30, 48]

Financial Performance - Total revenue for Q2 2025 reached $489.93 million, reflecting a 12% year-over-year increase[66] - Creative Subscriptions Annualized Recurring Revenue (ARR) stood at approximately $1.4 billion as of June 30, 2025, a 10% increase year-over-year[11, 24] - Total bookings for Q2 2025 amounted to $509.92 million, representing an 11% year-over-year growth[66] - The company anticipates generating a free cash flow (FCF) margin of 30-31% in 2025[58] - Non-GAAP gross margin was 70% in Q2 2025[67] Business Segments - Partners revenue for Q2 2025 was $183.32 million, a 24% increase year-over-year[11, 73] - Transaction revenue for Q2 2025 reached $63.55 million, an 18% increase year-over-year[11, 73] User Cohorts and Marketing - New cohort bookings growth accelerated to 14% in Q2 2025 over the Q2 2024 cohort[36] - The company estimates approximately $18.4 billion in expected future bookings over the next 10 years from existing cohorts[45] Geographic Reach - Approximately 40% of the company's revenue comes from outside North America[11] Acquisition - Wix acquired Base44 in June 2025, which is projected to generate $40-$50 million of ARR by the end of 2025[17]

Company Overview - Valens Semiconductor is a fabless semiconductor company listed on NYSE under the ticker VLN[13] - The company has shipped over 40 million chipsets and has over 100s of customers[13] - Valens has accumulated ~$05 billion in cumulative R&D expenses and holds 125 patents[13, 19] - In Q2 2025, Valens reported revenues of $171 million[13] Financial Performance - The company's revenue for 2024 was $579 million, with $363 million from Cross-Industry Business and $216 million from Automotive[68] - In Q2 2025, revenue was $171 million, with $128 million from Cross-Industry Business and $43 million from Automotive[69] - GAAP gross margin for Q2 2025 was 635%, with Cross-Industry Business at 678% and Automotive at 505%[71] - Adjusted EBITDA loss for Q2 2025 was $(40) million[71] Market Opportunities - The Total Addressable Market (TAM) for video conferencing is projected to reach $350 million by 2028/29[25] - The Total Addressable Market (TAM) for automotive is projected to reach $45 billion by 2029, with 14 billion chips per year[34] - The Total Addressable Market (TAM) for industrial machine vision is projected to reach $460 million by 2028/29[52] - The Total Addressable Market (TAM) for single-use endoscopy is projected to reach $625 million, assuming a 50% shift to single-use endoscopes[61] Future Outlook - The company is targeting revenue between $66 million and $71 million for 2025, representing a ~14%-23% year-over-year growth[72, 78] - Valens aims for revenue goals of $220-$300 million by 2029, with a CAGR of ~30%-~40% from 2024[75] - The company's long-term goals include a gross margin of 50%-60% and an adjusted EBITDA margin of 15%-20%[75, 80]

Financial Performance - Q3 FY25 revenue reached $3.6 billion, a 2% increase compared to $3.49 billion in Q3 FY24[43] - Adjusted EBITDA for Q3 FY25 was $274 million, up 7% from $257 million in Q3 FY24[43] - Adjusted Diluted EPS increased to $0.56 in Q3 FY25, compared to $0.51 in Q3 FY24[43] - Free Cash Flow for Q3 FY25 was $100 million[13] Business Development and Backlog - Backlog remained strong at $45 billion[13] - The company secured a Space Force Range Contract worth $4 billion, although it is currently under protest and not included in the backlog[22] - The company received multiple intelligence awards totaling over $500 million[24] - On-contract growth modifications and extensions provided a $2+ billion benefit in bookings[25] Debt and Deleveraging - Net leverage reduced to 3.5x, driven by operating and investing activity contributions[12, 52] - The company targets net leverage of less than 3x by FY26 year-end[54] - The company has $738 million in cash on hand and an $850 million undrawn revolving credit facility[57] Guidance - The company raised its FY25 organic revenue guidance to $13.975 - $14.175 billion[12, 58] - The company anticipates interest expense of $345M - $355M and capital expenditures of $35M - $40M for FY25[66] Nuclear Market - The global nuclear market demand is projected to reach $91 billion by FY2026 and $68 billion by FY2030[33] - The company's total addressable market in the nuclear sector is expected to more than double by 2035, reaching ~$20 billion[40]

Second Quarter 2025 Financial Results Call 1 Disclaimer Certain statements in this presentation may be considered "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements generally relate to future events or Holley's future financial or operating performance. For example, projections of future revenue and adjusted EBITDA and other metrics, along with statements regarding the impact of or ...